Michael Celano - 16 Sep 2022 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Reporting relationship: Chief Financial Officer
Issuer ticker: LRMR
Reported as of: 16 Sep 2022
Net transaction value: +$100,000
SEC form: 4
Accepted by SEC: 19 Sep 2022, 07:00:34 UTC
Prior SEC filing: 16 Aug 2022
Next SEC filing: 02 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Johansson, Attorney-in-fact

Key filing fact

Michael Celano filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 19 Sep 2022.

Key facts

This page summarizes Michael Celano's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Sep 2022, 07:00.

Change

Previous filing in this sequence was filed on 16 Aug 2022.
Current net transaction value: +$100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LRMR transaction

Common Stock

Purchase

Transaction value: $100,000
Shares: +31,746
Change %
Price: $3.15
Shares after: 31,746
Date: 16 Sep 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022.